Cytokinetics (CYTK) Tax Provisions (2010)
Cytokinetics (CYTK) posted quarterly Tax Provisions of -$176000.0 for Q3 2010.
Powered by 
Analysis
Cytokinetics (CYTK) Tax Provisions (2010) Analysis & Trends
Cytokinetics (CYTK) has reported Tax Provisions for 1 consecutive years, with -$176000.0 the latest figure, recorded in Q3 2010.
- In Q3 2010, Tax Provisions changed N/A year-over-year to -$176000.0; the TTM figure through Jun 2014 stood at -$176000.0 (changed N/A YoY), while the FY2010 annual figure was -$176000.0, down 217.33% from the prior year.
- Tax Provisions held at -$176000.0 in Q3 2010 per CYTK's latest filing.
- Across five years, Tax Provisions topped out at -$176000.0 in Q3 2010 and bottomed at -$176000.0 in Q3 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | - |